(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 April 2012 (19.04.2012)

PCT

(10) International Publication Number
WO 2012/051111 A2

(51) International Patent Classification:
C07K 16/24 (2006.01) *A61P 11/06* (2006.01)
A61K 39/395 (2006.01) *A61P 25/00* (2006.01)
C12N 15/13 (2006.01) *A61P 29/00* (2006.01)
C12N 5/10 (2006.01) *A61P 19/08* (2006.01)
C12P 21/02 (2006.01) *A61P 9/10* (2006.01)
A61P 19/02 (2006.01) *A61P 13/12* (2006.01)
A61P 17/06 (2006.01) *A61P 35/00* (2006.01)
A61P 11/00 (2006.01)

(21) International Application Number:
PCT/US2011/055606

(22) International Filing Date:
10 October 2011 (10.10.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/392,683 13 October 2010 (13.10.2010) US

(71) Applicant *(for all designated States except US)*: **JANSSEN BIOTECH, INC.** [US/US]; 800/ 850 Ridgeview Drive, Horsham, PA 19044 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ALMAGRO, Juan, Carlos** [US/US]; 145 King Of Prussia Road, Radnor, PA 19087 (US). **DUBELL, William** [US/US]; 145 King Of Prussia Road, Radnor, PA 19087 (US). **FRANSSON, Johan** [SE/US]; 3210 Merryfield Row, San Diego, CA 92121 (US). **PARDINAS, Jose** [US/US]; 145 King Of Prussia Road, Radnor, PA 19087 (US).

(74) Agents: **JOHNDON, Philip, S.** et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*


Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title**: HUMAN ONCOSTATIN M ANTIBODIES AND METHODS OF USE

Fig. 1



(57) **Abstract**: Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.

WO 2012/051111 A2